Bladder Cancer Treatment Guidelines Updated in 2026
The new recommendations help patients and doctors navigate treatment options for non-muscle invasive bladder cancer.
Updated on Oct. 3, 2026 in Cancer
Live Poll
Do you support medical guidelines that prioritize bladder-preserving treatments over traditional surgical options?
The American Urological Association and Society of Urologic Oncology released a 2026 amendment to the bladder cancer guideline on September 3, 2026. The update introduces 40 new recommendations for managing non-muscle invasive bladder cancer, which makes up 80% of all new U.S. cases.
Why it matters
This amendment provides clinicians with a structured framework for individualized decision-making regarding emerging therapies. It is intended to help medical professionals better navigate treatment options for the large majority of patients diagnosed with this specific form of bladder cancer.
The panel reviewed 38 studies published between May 2023 and December 2025 to form the updated evidence base. This systematic search analyzed data to support 40 new recommendations for the clinical management of non-muscle invasive bladder cancer.
The players
American Urological Association
A professional organization that establishes clinical practice standards for urologic health.
Society of Urologic Oncology
An association of medical professionals dedicated to advancing the care of patients with urologic cancers.
The details
The update incorporates new evidence into risk stratification, biomarker use, and surveillance strategies. Recommendations now specifically support active surveillance, office-based interventions, and chemoablation as options for recurrent low-grade disease. These approaches aim to refine how clinicians manage the condition while providing alternatives for patients seeking less invasive paths.
Timeline
May 2023 to December 2025: The systematic evidence search period for the panel.
September 3, 2026: The formal release and publication date of the guideline amendment.
Health Landscape
The updated guidance published in The Journal of Urology reflects a shift toward more personalized and less invasive management strategies for bladder cancer. This effort aligns with broader trends in oncology to minimize aggressive interventions for low-grade disease whenever clinically appropriate.
If you are managing bladder cancer, these guidelines offer updated options that are worth discussing with your doctor during your next visit. Specifically, ask if your treatment plan should be reviewed in light of the new recommendations regarding active surveillance or chemoablation.
The takeaway
The 2026 guideline update introduces new, evidence-based paths for managing non-muscle invasive bladder cancer. Patients should discuss these updated surveillance and treatment options with their urologist to ensure their care plan aligns with the most current medical standards.
Further reading
For more information on current treatment standards and diagnosis, visit the Cancer section.
More information
Review the full details regarding these updates in the AUA guideline amendment press release.
Source note: This article includes information reported by OncLive.
Live Poll
Do you support medical guidelines that prioritize bladder-preserving treatments over traditional surgical options?
